Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG)
Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) is a challenging condition to treat, and there is an unmet clinical need for effective therapies. Recently, polatuzumab vedotin (Pola), an anti-CD79b antibody-drug-conjugate (ADC), combined with bendamustine-rituximab (BR), has been appro...
Gespeichert in:
| Veröffentlicht in: | Annals of hematology 2023-07, Vol.102 (7), p.1887-1895 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1895 |
|---|---|
| container_issue | 7 |
| container_start_page | 1887 |
| container_title | Annals of hematology |
| container_volume | 102 |
| creator | Rattanathammethee, Thanawat Norasetthada, Lalita Bunworasate, Udomsak Wudhikarn, Kitsada Julamanee, Jakrawadee Noiperm, Panarat Lanamtieng, Theerin Phiphitaporn, Pisa Navinpipat, Manassamon Kanya, Piyapong Jit-ueakul, Dusit Wongkhantee, Somchai Suwannathen, Thanongsak Chaloemwong, Juthatip Wong, Peerapon Makruasi, Nisa Khuhapinant, Archrob Prayongratana, Kannadit Niparuck, Pimjai Kanitsap, Nonglak Suwanban, Tawatchai Intragumtornchai, Tanin |
| description | Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) is a challenging condition to treat, and there is an unmet clinical need for effective therapies. Recently, polatuzumab vedotin (Pola), an anti-CD79b antibody-drug-conjugate (ADC), combined with bendamustine-rituximab (BR), has been approved for R/R DLBCL patients. However, real-world data on Pola-based regimens in R/R DLBCL patients, especially in Thailand, are limited. This study aimed to evaluate the efficacy and safety of Pola-based salvage treatment in R/R DLBCL patients in Thailand. Thirty-five patients who received Pola-based treatment were included in the study, and their data were compared to 180 matched patients who received non-Pola-based therapy. The overall response rate (ORR) in the Pola group was 62.8%, with complete remission and partial remission rates of 17.1% and 45.7%, respectively. The median progression-free survival (PFS) and overall survival (OS) were 10.6 months and 12.8 months, respectively. The study found a significantly higher ORR in Pola-based salvage treatments compared to non-Pola-based therapy (62.8% vs. 33.3%). The survival outcomes were also significantly superior in the Pola group, with longer median PFS and OS than the control group. Grades 3–4 adverse events (AEs) were mainly hematological, and they were tolerable. In conclusion, this study provides real-world evidence of the efficacy and safety of Pola-based salvage treatment in R/R DLBCL patients in Thailand. The results of this study are promising and suggest that Pola-based salvage treatment could be a viable option for R/R DLBCL patients who have limited treatment options. |
| doi_str_mv | 10.1007/s00277-023-05273-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2816762223</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2816762223</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-7329c151261ac47f90092857b0da26663a3829322d8d621be0ffe341052005bc3</originalsourceid><addsrcrecordid>eNp9kc9uFDEMxkcIRJfCC3BAlriUQyBx5i-3UsGCtFIPXc6jTJLZTZVMhiQDWp6TByLbbUHiQC6O5Z8_y_6K4iWjbxmlzbtIKTYNocgJrbDhpH1UrFjJMadt-bhY0Y53pMrvrHgW4y2lDNsSnxZnvEGKZdetil_XS5Le6Qh-hNlbkZafixMDfNfKJzMR6ackzGSmHQS9M05PEcyU_8KSHz5YBVGndCxngaCtmKNWICYFPuR8DEImHw6gzDguUYMVYafhA5HaWrAHN--9EzCLZPSU4nsQ4ESSe63uJgdvs5awh2gijME7SHsN270wsHnovUmLOsA6-GWGi-3mZv3mefFkFDbqF_fxvPj66eP26jPZXK-_XF1uiORNlUjDsZOsYlgzIctm7CjtsK2agSqBdV1zwVvsOKJqVY1s0HQcNS9ZPjal1SD5eXFx0p2D_7bomHpn4nExMWm_xB5bVjc1IvKMvv4HvfVLyJsdKayquuQ1ZgpPlAw-xny9fg7GiXDoGe2Pnvcnz_vseX_ned_mplf30svgtPrT8mByBvgJiLk07XT4O_s_sr8B8Pm5ww</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2825564362</pqid></control><display><type>article</type><title>Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG)</title><source>SpringerNature Journals</source><creator>Rattanathammethee, Thanawat ; Norasetthada, Lalita ; Bunworasate, Udomsak ; Wudhikarn, Kitsada ; Julamanee, Jakrawadee ; Noiperm, Panarat ; Lanamtieng, Theerin ; Phiphitaporn, Pisa ; Navinpipat, Manassamon ; Kanya, Piyapong ; Jit-ueakul, Dusit ; Wongkhantee, Somchai ; Suwannathen, Thanongsak ; Chaloemwong, Juthatip ; Wong, Peerapon ; Makruasi, Nisa ; Khuhapinant, Archrob ; Prayongratana, Kannadit ; Niparuck, Pimjai ; Kanitsap, Nonglak ; Suwanban, Tawatchai ; Intragumtornchai, Tanin</creator><creatorcontrib>Rattanathammethee, Thanawat ; Norasetthada, Lalita ; Bunworasate, Udomsak ; Wudhikarn, Kitsada ; Julamanee, Jakrawadee ; Noiperm, Panarat ; Lanamtieng, Theerin ; Phiphitaporn, Pisa ; Navinpipat, Manassamon ; Kanya, Piyapong ; Jit-ueakul, Dusit ; Wongkhantee, Somchai ; Suwannathen, Thanongsak ; Chaloemwong, Juthatip ; Wong, Peerapon ; Makruasi, Nisa ; Khuhapinant, Archrob ; Prayongratana, Kannadit ; Niparuck, Pimjai ; Kanitsap, Nonglak ; Suwanban, Tawatchai ; Intragumtornchai, Tanin</creatorcontrib><description>Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) is a challenging condition to treat, and there is an unmet clinical need for effective therapies. Recently, polatuzumab vedotin (Pola), an anti-CD79b antibody-drug-conjugate (ADC), combined with bendamustine-rituximab (BR), has been approved for R/R DLBCL patients. However, real-world data on Pola-based regimens in R/R DLBCL patients, especially in Thailand, are limited. This study aimed to evaluate the efficacy and safety of Pola-based salvage treatment in R/R DLBCL patients in Thailand. Thirty-five patients who received Pola-based treatment were included in the study, and their data were compared to 180 matched patients who received non-Pola-based therapy. The overall response rate (ORR) in the Pola group was 62.8%, with complete remission and partial remission rates of 17.1% and 45.7%, respectively. The median progression-free survival (PFS) and overall survival (OS) were 10.6 months and 12.8 months, respectively. The study found a significantly higher ORR in Pola-based salvage treatments compared to non-Pola-based therapy (62.8% vs. 33.3%). The survival outcomes were also significantly superior in the Pola group, with longer median PFS and OS than the control group. Grades 3–4 adverse events (AEs) were mainly hematological, and they were tolerable. In conclusion, this study provides real-world evidence of the efficacy and safety of Pola-based salvage treatment in R/R DLBCL patients in Thailand. The results of this study are promising and suggest that Pola-based salvage treatment could be a viable option for R/R DLBCL patients who have limited treatment options.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-023-05273-8</identifier><identifier>PMID: 37202499</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Hematology ; Lymphoma ; Medicine ; Medicine & Public Health ; Oncology ; Original Article</subject><ispartof>Annals of hematology, 2023-07, Vol.102 (7), p.1887-1895</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-7329c151261ac47f90092857b0da26663a3829322d8d621be0ffe341052005bc3</citedby><cites>FETCH-LOGICAL-c375t-7329c151261ac47f90092857b0da26663a3829322d8d621be0ffe341052005bc3</cites><orcidid>0000-0002-1073-8872 ; 0000-0002-8887-4292 ; 0000-0002-2223-5711 ; 0000-0001-9528-8681 ; 0000-0002-6930-258X ; 0000-0001-8843-4003 ; 0000-0002-6526-9479 ; 0000-0003-2731-4889 ; 0000-0002-1231-0212 ; 0000-0002-4967-7237</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00277-023-05273-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00277-023-05273-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37202499$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rattanathammethee, Thanawat</creatorcontrib><creatorcontrib>Norasetthada, Lalita</creatorcontrib><creatorcontrib>Bunworasate, Udomsak</creatorcontrib><creatorcontrib>Wudhikarn, Kitsada</creatorcontrib><creatorcontrib>Julamanee, Jakrawadee</creatorcontrib><creatorcontrib>Noiperm, Panarat</creatorcontrib><creatorcontrib>Lanamtieng, Theerin</creatorcontrib><creatorcontrib>Phiphitaporn, Pisa</creatorcontrib><creatorcontrib>Navinpipat, Manassamon</creatorcontrib><creatorcontrib>Kanya, Piyapong</creatorcontrib><creatorcontrib>Jit-ueakul, Dusit</creatorcontrib><creatorcontrib>Wongkhantee, Somchai</creatorcontrib><creatorcontrib>Suwannathen, Thanongsak</creatorcontrib><creatorcontrib>Chaloemwong, Juthatip</creatorcontrib><creatorcontrib>Wong, Peerapon</creatorcontrib><creatorcontrib>Makruasi, Nisa</creatorcontrib><creatorcontrib>Khuhapinant, Archrob</creatorcontrib><creatorcontrib>Prayongratana, Kannadit</creatorcontrib><creatorcontrib>Niparuck, Pimjai</creatorcontrib><creatorcontrib>Kanitsap, Nonglak</creatorcontrib><creatorcontrib>Suwanban, Tawatchai</creatorcontrib><creatorcontrib>Intragumtornchai, Tanin</creatorcontrib><title>Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG)</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><addtitle>Ann Hematol</addtitle><description>Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) is a challenging condition to treat, and there is an unmet clinical need for effective therapies. Recently, polatuzumab vedotin (Pola), an anti-CD79b antibody-drug-conjugate (ADC), combined with bendamustine-rituximab (BR), has been approved for R/R DLBCL patients. However, real-world data on Pola-based regimens in R/R DLBCL patients, especially in Thailand, are limited. This study aimed to evaluate the efficacy and safety of Pola-based salvage treatment in R/R DLBCL patients in Thailand. Thirty-five patients who received Pola-based treatment were included in the study, and their data were compared to 180 matched patients who received non-Pola-based therapy. The overall response rate (ORR) in the Pola group was 62.8%, with complete remission and partial remission rates of 17.1% and 45.7%, respectively. The median progression-free survival (PFS) and overall survival (OS) were 10.6 months and 12.8 months, respectively. The study found a significantly higher ORR in Pola-based salvage treatments compared to non-Pola-based therapy (62.8% vs. 33.3%). The survival outcomes were also significantly superior in the Pola group, with longer median PFS and OS than the control group. Grades 3–4 adverse events (AEs) were mainly hematological, and they were tolerable. In conclusion, this study provides real-world evidence of the efficacy and safety of Pola-based salvage treatment in R/R DLBCL patients in Thailand. The results of this study are promising and suggest that Pola-based salvage treatment could be a viable option for R/R DLBCL patients who have limited treatment options.</description><subject>Hematology</subject><subject>Lymphoma</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Original Article</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kc9uFDEMxkcIRJfCC3BAlriUQyBx5i-3UsGCtFIPXc6jTJLZTZVMhiQDWp6TByLbbUHiQC6O5Z8_y_6K4iWjbxmlzbtIKTYNocgJrbDhpH1UrFjJMadt-bhY0Y53pMrvrHgW4y2lDNsSnxZnvEGKZdetil_XS5Le6Qh-hNlbkZafixMDfNfKJzMR6ackzGSmHQS9M05PEcyU_8KSHz5YBVGndCxngaCtmKNWICYFPuR8DEImHw6gzDguUYMVYafhA5HaWrAHN--9EzCLZPSU4nsQ4ESSe63uJgdvs5awh2gijME7SHsN270wsHnovUmLOsA6-GWGi-3mZv3mefFkFDbqF_fxvPj66eP26jPZXK-_XF1uiORNlUjDsZOsYlgzIctm7CjtsK2agSqBdV1zwVvsOKJqVY1s0HQcNS9ZPjal1SD5eXFx0p2D_7bomHpn4nExMWm_xB5bVjc1IvKMvv4HvfVLyJsdKayquuQ1ZgpPlAw-xny9fg7GiXDoGe2Pnvcnz_vseX_ned_mplf30svgtPrT8mByBvgJiLk07XT4O_s_sr8B8Pm5ww</recordid><startdate>20230701</startdate><enddate>20230701</enddate><creator>Rattanathammethee, Thanawat</creator><creator>Norasetthada, Lalita</creator><creator>Bunworasate, Udomsak</creator><creator>Wudhikarn, Kitsada</creator><creator>Julamanee, Jakrawadee</creator><creator>Noiperm, Panarat</creator><creator>Lanamtieng, Theerin</creator><creator>Phiphitaporn, Pisa</creator><creator>Navinpipat, Manassamon</creator><creator>Kanya, Piyapong</creator><creator>Jit-ueakul, Dusit</creator><creator>Wongkhantee, Somchai</creator><creator>Suwannathen, Thanongsak</creator><creator>Chaloemwong, Juthatip</creator><creator>Wong, Peerapon</creator><creator>Makruasi, Nisa</creator><creator>Khuhapinant, Archrob</creator><creator>Prayongratana, Kannadit</creator><creator>Niparuck, Pimjai</creator><creator>Kanitsap, Nonglak</creator><creator>Suwanban, Tawatchai</creator><creator>Intragumtornchai, Tanin</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1073-8872</orcidid><orcidid>https://orcid.org/0000-0002-8887-4292</orcidid><orcidid>https://orcid.org/0000-0002-2223-5711</orcidid><orcidid>https://orcid.org/0000-0001-9528-8681</orcidid><orcidid>https://orcid.org/0000-0002-6930-258X</orcidid><orcidid>https://orcid.org/0000-0001-8843-4003</orcidid><orcidid>https://orcid.org/0000-0002-6526-9479</orcidid><orcidid>https://orcid.org/0000-0003-2731-4889</orcidid><orcidid>https://orcid.org/0000-0002-1231-0212</orcidid><orcidid>https://orcid.org/0000-0002-4967-7237</orcidid></search><sort><creationdate>20230701</creationdate><title>Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG)</title><author>Rattanathammethee, Thanawat ; Norasetthada, Lalita ; Bunworasate, Udomsak ; Wudhikarn, Kitsada ; Julamanee, Jakrawadee ; Noiperm, Panarat ; Lanamtieng, Theerin ; Phiphitaporn, Pisa ; Navinpipat, Manassamon ; Kanya, Piyapong ; Jit-ueakul, Dusit ; Wongkhantee, Somchai ; Suwannathen, Thanongsak ; Chaloemwong, Juthatip ; Wong, Peerapon ; Makruasi, Nisa ; Khuhapinant, Archrob ; Prayongratana, Kannadit ; Niparuck, Pimjai ; Kanitsap, Nonglak ; Suwanban, Tawatchai ; Intragumtornchai, Tanin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-7329c151261ac47f90092857b0da26663a3829322d8d621be0ffe341052005bc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Hematology</topic><topic>Lymphoma</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Original Article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rattanathammethee, Thanawat</creatorcontrib><creatorcontrib>Norasetthada, Lalita</creatorcontrib><creatorcontrib>Bunworasate, Udomsak</creatorcontrib><creatorcontrib>Wudhikarn, Kitsada</creatorcontrib><creatorcontrib>Julamanee, Jakrawadee</creatorcontrib><creatorcontrib>Noiperm, Panarat</creatorcontrib><creatorcontrib>Lanamtieng, Theerin</creatorcontrib><creatorcontrib>Phiphitaporn, Pisa</creatorcontrib><creatorcontrib>Navinpipat, Manassamon</creatorcontrib><creatorcontrib>Kanya, Piyapong</creatorcontrib><creatorcontrib>Jit-ueakul, Dusit</creatorcontrib><creatorcontrib>Wongkhantee, Somchai</creatorcontrib><creatorcontrib>Suwannathen, Thanongsak</creatorcontrib><creatorcontrib>Chaloemwong, Juthatip</creatorcontrib><creatorcontrib>Wong, Peerapon</creatorcontrib><creatorcontrib>Makruasi, Nisa</creatorcontrib><creatorcontrib>Khuhapinant, Archrob</creatorcontrib><creatorcontrib>Prayongratana, Kannadit</creatorcontrib><creatorcontrib>Niparuck, Pimjai</creatorcontrib><creatorcontrib>Kanitsap, Nonglak</creatorcontrib><creatorcontrib>Suwanban, Tawatchai</creatorcontrib><creatorcontrib>Intragumtornchai, Tanin</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rattanathammethee, Thanawat</au><au>Norasetthada, Lalita</au><au>Bunworasate, Udomsak</au><au>Wudhikarn, Kitsada</au><au>Julamanee, Jakrawadee</au><au>Noiperm, Panarat</au><au>Lanamtieng, Theerin</au><au>Phiphitaporn, Pisa</au><au>Navinpipat, Manassamon</au><au>Kanya, Piyapong</au><au>Jit-ueakul, Dusit</au><au>Wongkhantee, Somchai</au><au>Suwannathen, Thanongsak</au><au>Chaloemwong, Juthatip</au><au>Wong, Peerapon</au><au>Makruasi, Nisa</au><au>Khuhapinant, Archrob</au><au>Prayongratana, Kannadit</au><au>Niparuck, Pimjai</au><au>Kanitsap, Nonglak</au><au>Suwanban, Tawatchai</au><au>Intragumtornchai, Tanin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG)</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><addtitle>Ann Hematol</addtitle><date>2023-07-01</date><risdate>2023</risdate><volume>102</volume><issue>7</issue><spage>1887</spage><epage>1895</epage><pages>1887-1895</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) is a challenging condition to treat, and there is an unmet clinical need for effective therapies. Recently, polatuzumab vedotin (Pola), an anti-CD79b antibody-drug-conjugate (ADC), combined with bendamustine-rituximab (BR), has been approved for R/R DLBCL patients. However, real-world data on Pola-based regimens in R/R DLBCL patients, especially in Thailand, are limited. This study aimed to evaluate the efficacy and safety of Pola-based salvage treatment in R/R DLBCL patients in Thailand. Thirty-five patients who received Pola-based treatment were included in the study, and their data were compared to 180 matched patients who received non-Pola-based therapy. The overall response rate (ORR) in the Pola group was 62.8%, with complete remission and partial remission rates of 17.1% and 45.7%, respectively. The median progression-free survival (PFS) and overall survival (OS) were 10.6 months and 12.8 months, respectively. The study found a significantly higher ORR in Pola-based salvage treatments compared to non-Pola-based therapy (62.8% vs. 33.3%). The survival outcomes were also significantly superior in the Pola group, with longer median PFS and OS than the control group. Grades 3–4 adverse events (AEs) were mainly hematological, and they were tolerable. In conclusion, this study provides real-world evidence of the efficacy and safety of Pola-based salvage treatment in R/R DLBCL patients in Thailand. The results of this study are promising and suggest that Pola-based salvage treatment could be a viable option for R/R DLBCL patients who have limited treatment options.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>37202499</pmid><doi>10.1007/s00277-023-05273-8</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-1073-8872</orcidid><orcidid>https://orcid.org/0000-0002-8887-4292</orcidid><orcidid>https://orcid.org/0000-0002-2223-5711</orcidid><orcidid>https://orcid.org/0000-0001-9528-8681</orcidid><orcidid>https://orcid.org/0000-0002-6930-258X</orcidid><orcidid>https://orcid.org/0000-0001-8843-4003</orcidid><orcidid>https://orcid.org/0000-0002-6526-9479</orcidid><orcidid>https://orcid.org/0000-0003-2731-4889</orcidid><orcidid>https://orcid.org/0000-0002-1231-0212</orcidid><orcidid>https://orcid.org/0000-0002-4967-7237</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2023-07, Vol.102 (7), p.1887-1895 |
| issn | 0939-5555 1432-0584 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2816762223 |
| source | SpringerNature Journals |
| subjects | Hematology Lymphoma Medicine Medicine & Public Health Oncology Original Article |
| title | Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T19%3A24%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcomes%20of%20polatuzumab%20vedotin-containing%20regimens%20in%20real-world%20setting%20of%20relapsed%20and%20or%20refractory%20diffuse%20large%20B-cell%20lymphoma%20patients:%20a%20matched-control%20analysis%20from%20the%20Thai%20Lymphoma%20Study%20Group%20(TLSG)&rft.jtitle=Annals%20of%20hematology&rft.au=Rattanathammethee,%20Thanawat&rft.date=2023-07-01&rft.volume=102&rft.issue=7&rft.spage=1887&rft.epage=1895&rft.pages=1887-1895&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-023-05273-8&rft_dat=%3Cproquest_cross%3E2816762223%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2825564362&rft_id=info:pmid/37202499&rfr_iscdi=true |